ArticleERJ open research2017
High PD-1 expression on regulatory and effector T-cells in lung cancer draining lymph nodes.
Article in ERJ open research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Tumor draining lymph nodes in non-small cell lung cancer:Frontiers in immunology · 2026Review
- Harnessing the power of tumor-draining lymph nodes: unveiling predictive biomarkers for immune checkpoint inhibitor.Exploration of targeted anti-tumor therapy · 2025Review
- Tumor-draining lymph nodes: opportunities, challenges, and future directions in colorectal cancer immunotherapy.Journal for immunotherapy of cancer · 2024Review
- Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodes.Oncoimmunology · 2023Article
- Immunosuppressive properties of human PD-1 + , PDL-1 + and CD80 + dendritic cells from lymph nodes aspirates of lung cancer patients.Cancer immunology, immunotherapy : CII · 2022Article
- Immune Checkpoint Therapy: Tumor Draining Lymph Nodes in the Spotlights.International journal of molecular sciences · 2021Review
- Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab.Scientific reports · 2021Article
- CD4Cancer science · 2021Observational
- PD-L1Cancer immunology, immunotherapy : CII · 2021Article
- Lymph Node Immune Profiles as Predictive Biomarkers for Immune Checkpoint Inhibitor Response.Frontiers in molecular biosciences · 2021Review
- Bronchoscopic intratumoural therapies for non-small cell lung cancer.European respiratory review : an official journal of the European Respiratory Society · 2020Review
- Article
- Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy.Frontiers in immunology · 2020Review
- PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.The oncologist · 2019Review
- An engineered PD-1-based and MMP-2/9-oriented fusion protein exerts potent antitumor effects against melanoma.BMB reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment of advanced nonsmall cell lung cancer (NSCLC) with PD-1/PD-L1 immune checkpoint inhibitors has improved clinical outcome for a proportion of patients. The current challenge is to find better biomarkers than PD-L1 immunohistochemistry (IHC) that will identify patients likely to benefit from this therapy. In this exploratory study we assessed the differences in T-cell subsets and PD-1 expression levels on T-cells in tumour-draining lymph nodes (TDLNs) and peripheral blood mononuclear cells (PBMCs). To evaluate this, flow cytometric analyses were performed on endobronchial ultrasound-guided (EBUS) fine-needle aspirates (FNA) from TDLNs of patients with NSCLC, and the results were compared to paired PBMC samples. For a select number of patients, we were also able to obtain cells from a non-TDLN (NTDLN) sample. Our data show that the frequency of PD-1
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.